Inventiva stock drops 25.5% over one month, support level at €2.77 at stake
The biotech company specializing in fibrotic and metabolic diseases is making slight progress this Tuesday, in a quasi-stable SBF 120. TD Cowen has revised down its price target while maintaining its positive opinion on the stock, in a context where Inventiva's publication of its half-yearly accounts is now behind it.
TD Cowen maintains buy rating but lowers price target to €9 on Inventiva
This Tuesday, September 29, Inventiva benefits from a favorable opinion from TD Cowen, which maintains its buy rating while reducing its price target from €10 to €9. This €9 threshold represents an upside potential of over 200% compared to the current price of €2.97, illustrating the considerable gap between the market's current valuation and that retained by this research firm. According to analyst consensus, the stock thus retains a bullish profile, even though the downward revision of the target reflects increased caution. This positioning comes after the publication of the unaudited accounts for the first half of 2026, when Inventiva had announced cash and cash equivalents of €166.1 million as of June 30, 2026, following a major financing restructuring comprising a €103 million share offering and a €75 million financing transaction announced in June.
Inventiva below its moving averages with RSI at 29 ahead of NATiV3 phase 3 results
In terms of market indicators, the stock is trading at €2.97, well below its three moving averages: the 20-day MA at €3.48 (down 14.8%), the 50-day MA at €3.78 (down 21.6%) and the 200-day MA at €4.30 (down 31%). This configuration reflects the accumulated selling pressure over several weeks, with a decline of 25.9% over one month. The RSI at 29 remains in oversold territory, without a clear reversal signal emerging yet.
Inventiva is nevertheless holding above its support level at €2.77, which is the level to watch in the coming sessions. The most structuring horizon remains the publication of the primary results of the phase 3 NATiV3 pivotal study, focusing on the lanifibranor drug candidate in MASH (metabolic steatohepatitis), expected in the fourth quarter of 2026.
